With the rising global mental health crisis, over 1 billion people are afflicted with stress-related disorders like depression, sleep disorders, anxiety, substance abuse and PTSD. Researchers are looking increasingly toward the potential of psychedelic compounds as a treatment to help improve the quality of life for these patients.

Supported by exciting early scientific evidence, this fledgling industry is gaining momentum. At Transpharmation, we carry out sponsored preclinical translational in vivo pharmacology research into ketamine, psilocybin, LSD, psilocin, 5-MeO-DMT, 2C-B, NBOMe derivatives, MDMA, MDA, mitragynine, cathinone and other psychedelics, for the treatment of neuropsychiatric disorders, providing the necessary data to propel compounds into the clinic.

Examples of psychedelic-relevant assays we offer:

  • Target engagement - Mouse head twitch / Rat WDS
  • Anxiety assays - Open Field
  • Depression assays - Chronic Social Defeat, Progressive Ratio
  • Developed Bioanalytical Assays and PK
  • Sleep / QEEG - Eg; REM suppression, Power spectral analysis
  • Safety profiling - Locomotor activity, Serotonin syndrome, Seizure threshold
  • Molecular biomarkers - Inflammatory cytokine profiling, LPS-induced neuroinflammation (in vivo & ex vivo)
  • Pain assays - Inflammatory pain (CFA, UV-Burn, Etc) Neuropathic pain (CCI, CIPN, Etc)
  • Seizure threshold assays - Chemical & Electrical induced seizure assays (Eg: MEST, PTZ, Etc), Tremor
Psilocybin and MDMA are available for internal and external studies and storage/logistics of controlled substances. Please feel free to reach out to us to discuss your research needs.

Models

Platforms used

Also part of

Have a program in mind?

Talk to a Transpharmation researcher about your study design and timelines.

Speak to a researcher